Drugs / AceDoPC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02168738 | Mar 2014 → Apr 2015 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AceDoPC | “AceDoPC® is a structured glycerophospholipid that targets the brain with docosahexaenoic acid (DHA) and is neuroprotective in the experimental ischemic stroke.” PMID 31963708 ↗ Jan 2020 |
| Modality | Other / unclassified | “AceDoPC® is a structured glycerophospholipid” PMID 31963708 ↗ Jan 2020 |
| Route | Oral | “after oral intake of a single dose of 13C-AceDoPC®” PMID 31963708 ↗ Jan 2020 |